Abstract

As essential micronutrients, metal ions such as iron, manganese, copper, and zinc, are required for a wide range of physiological processes in the brain. However, an imbalance in metal ions, whether excessive or insufficient, is detrimental and can contribute to neuronal death through oxidative stress, ferroptosis, cuproptosis, cell senescence, or neuroinflammation. These processes have been found to be involved in the pathological mechanisms of neurodegenerative diseases. In this review, the research history and milestone events of studying metal ions, including iron, manganese, copper, and zinc in neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), will be introduced. Then, the upstream regulators, downstream effector, and crosstalk of mental ions under both physiologic and pathologic conditions will be summarized. Finally, the therapeutic effects of metal ion chelators, such as clioquinol, quercetin, curcumin, coumarin, and their derivatives for the treatment of neurodegenerative diseases will be discussed. Additionally, the promising results and limitations observed in clinical trials of these metal ion chelators will also be addressed. This review will not only provide a comprehensive understanding of the role of metal ions in disease development but also offer perspectives on their modulation for the prevention or treatment of neurodegenerative diseases.

MeSH

Chelating Agents, Homeostasis, Signal Transduction, Therapeutics, Neurodegenerative Diseases

Cited by

• Fisetin Attenuates Zinc Overload-Induced Hepatotoxicity in Mice via Autophagy-Dependent Nrf2 Activation. Int J Mol Sci, 2025
• The Redox Revolution in Brain Medicine: Targeting Oxidative Stress with AI, Multi-Omics and Mitochondrial Therapies for the Precision Eradication of Neurodegeneration. Int J Mol Sci, 2025
• Precision Recovery After Spinal Cord Injury: Integrating CRISPR Technologies, AI-Driven Therapeutics, Single-Cell Omics, and System Neuroregeneration. Int J Mol Sci, 2025
• Ferroptosis in neurodegenerative diseases: potential mechanisms of exercise intervention. Front Cell Dev Biol, 2025
• New Antioxidant Triphenol-Derived Hydrazide-Hydrazone Thiazole: Formation and Analysis of Inclusion Complex with β-CD Using Experimental and Computational Approaches. Molecules, 2025
• Rational Modulation of Liquid-Liquid Phase Separation Offers Novel Ways to Combat Tauopathies. Int J Mol Sci, 2025
• Paramagnetic susceptibility mapping better quantifies brain iron content in Parkinson's disease with RBD. NPJ Parkinsons Dis, 2025
• Tailorable bimetallic nanozyme mitigates intervertebral disc degeneration by inhibiting oxidative stress and inflammageing. Theranostics, 2025
• Actual Data on Essential Trace Elements in Parkinson's Disease. Nutrients, 2025
• Balancing between cuproplasia and copper-dependent cell death: molecular basis and clinical implications of ATOX1 in cancer. J Exp Clin Cancer Res, 2025
• Understanding Causal Relationships Between Imaging-Derived Phenotypes and Parkinson's Disease: A Mendelian Randomization and Observational Study. Biomedicines, 2025
• Herbal Interventions in Parkinson's Disease: A Systematic Review of Preclinical Studies. Cell Mol Neurobiol, 2025
• Ceruloplasmin and Ferritin Changes in Ocular Fluids from Patients with Vitreoretinal Diseases: Relation with Neuroinflammation and Drusen Formation. Int J Mol Sci, 2025
• Iron overload exaggerates renal ischemia-reperfusion injury by promoting tubular cuproptosis via interrupting function of LIAS. Redox Biol, 2025
• Salicylaldehyde Benzoylhydrazone Protects Against Ferroptosis in Models of Neurotoxicity and Behavioural Dysfunction, In Vitro and In Vivo. J Mol Neurosci, 2025
• Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis. Int J Mol Sci, 2025
• Quercetin as a Therapeutic Option in a Rat Model of Aluminum Chloride- and D-Galactose-Induced Neurodegeneration. Int J Mol Sci, 2025